Effect of BG-12 (Dimethyl Fumarate) in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from Two Phase 3 Studies (DEFINE and CONFIRM)

被引：0
|
作者：
Hutchinson, M. [1 ]
Bar-Or, A. [2 ]
Fox, R. J. [3 ]
Gold, R. [4 ]
Giovannoni, G. [5 ]
Kita, M. [6 ]
O'Gorman, J. [7 ]
Yang, M. [7 ]
Sheikh, S. I. [7 ]
Viglietta, V. [7 ]
Dawson, K. T. [7 ]
机构：
[1] St Vincents Univ Hosp, Dublin 4, Ireland
[2] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada
[3] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[4] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[5] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[6] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[7] Biogen Idec Inc, Weston, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：682 / 683
页数：2
相关论文
共 50 条
  • [41] Flushing and gastrointestinal tolerability events in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 dimethyl fumarate) in the phase 3 DEFINE and CONFIRM trials
    Selmaj, K.
    Gold, R.
    Fox, R. J.
    Havrdova, E.
    Giovannoni, G.
    Pace, A.
    Novas, M.
    Meltzer, L.
    Hotermans, C.
    Viglietta, V.
    Phillips, J. T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 221 - 221
  • [42] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
    Michael Hutchinson
    Robert J. Fox
    David H. Miller
    J. Theodore Phillips
    Mariko Kita
    Eva Havrdova
    John O’Gorman
    Ray Zhang
    Mark Novas
    Vissia Viglietta
    Katherine T. Dawson
    Journal of Neurology, 2013, 260 : 2286 - 2296
  • [43] Effects of BG-12 on magnetic resonance imaging outcomes in relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Miller, D. H.
    Gold, R.
    Fox, R. J.
    MacManus, D.
    Yousry, T.
    Bar-Or, A.
    Zhang, R.
    Viglietta, V.
    Stephan, M.
    Dawson, K. T.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 418 - 418
  • [44] 3-Year Follow-up of Oral BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated MRI Outcomes from the DEFINE, CONFIRM, and ENDORSE studies
    Miller, D. H.
    Fox, R. J.
    Gold, R.
    Havrdova, E.
    Kappos, L.
    Yousry, T.
    Rana, J.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Sheikh, S. I.
    Dawson, K. T.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 932 - 932
  • [45] Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study
    Amit Bar-Or
    Ralf Gold
    Ludwig Kappos
    Douglas L. Arnold
    Gavin Giovannoni
    Krzysztof Selmaj
    John O’Gorman
    Monica Stephan
    Katherine T. Dawson
    Journal of Neurology, 2013, 260 : 2297 - 2305
  • [46] Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study
    Fox, Robert
    Miller, David
    Phillips, J. Theodore
    Kita, Mariko
    Hutchinson, Michael
    Havrdova, Eva
    Yang, Minhua
    Zhang, Ray
    Viglietta, Vissia
    Dawson, Katherine
    NEUROLOGY, 2012, 78
  • [47] An integrated analysis of safety and tolerability of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from phase 2 and 3 placebo-controlled studies
    Phillips, J. T.
    Fox, R. J.
    Gold, R.
    Havrdova, E.
    Kappos, L.
    Raghupathi, K.
    Yuan, H.
    Viglietta, V.
    Sheikh, S. I.
    Dawson, K. T.
    Novas, M.
    Sweetser, M. T.
    Selmaj, K.
    JOURNAL OF NEUROLOGY, 2013, 260 : S75 - S75
  • [48] Safety and Tolerability of BG-12 (Dimethyl Fumarate) in Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of Phase 2 and 3 Placebo-Controlled Studies
    Phillips, J. Theodore
    Fox, Robert
    Gold, Ralf
    Havrdova, Eva
    Kappos, Ludwig
    Raghupathi, Kartik
    Yuan, Huixing
    Viglietta, Vissia
    Sheikh, Sarah
    Dawson, Katherine
    Novas, Mark
    Sweetser, Marianne
    Selmaj, Krzysztof
    NEUROLOGY, 2013, 80
  • [49] Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
    Nakamura, Kunio
    Mokliatchouk, Oksana
    Arnold, Douglas L.
    Yousry, Tarek A.
    Kappos, Ludwig
    Richert, Nancy
    Ayling-Rouse, Katherine
    Miller, Catherine
    Fisher, Elizabeth
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [50] Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses From the CONFIRM Study
    Phillips, J. Theodore
    Fox, Robert
    Miller, David
    Kita, Mariko
    Hutchinson, Michael
    Havrdova, Eva
    Raghupathi, Kartik
    Yuan, Huixing
    Novas, Mark
    Viglietta, Vissia
    Dawson, Katherine
    NEUROLOGY, 2012, 78
12345